Organic Letters
Letter
11R chiral center, we examined stereoselective allylation under
various conditions. Eventually, when 31 was treated with
allyltributylstannane and magnesium bromide ethyl etherate
(MgBr2·Et2O) in CH2Cl2 at 0 °C according to Linclau’s
method,22 the allylation was found to take place with perfect
chemo- and diastereoselectivities to afford 3323 in excellent
yield. The selective allylation can be rationalized via chelated
intermediate 32 where the re face attack of the allyl nucleophile
is favored by steric reasons. After silylation of 33, all our efforts
for Z-selective RCM24 of 34 using various metathesis catalysts
were totally fruitless, giving only unreacted 34. However, the
RCM reaction in the presence of classic Grubbs first
generation catalyst in boiling CH2Cl2 afforded the desired Z-
product 5 in 27% yield.25 Compound 5, thus obtained,
exhibited spectral properties identical in all respects to those
reported by Huang et al.3 Therefore, the formal synthesis of
(−)-haliclonin A (1) was achieved.
In conclusion, we have developed a novel approach for the
synthesis of (−)-haliclonin A (1) in an enantiomerically pure
form. The present work illustrates an efficient methodology for
the enantio- and diastereoselective construction of highly
functionalized azabicyclo[3.3.1]nonane ring systems which
relies on Pd-mediated deracemization of cyclohexenyl ester
derivatives and the tandem radical cyclization−allylation
process.
ACKNOWLEDGMENTS
■
This work was supported by JSPS KAKENHI Grants
JP16J03966 (K.K.), JP19K15568 (K.K.), JP16H05074
(S.H.), and JP18K05126 (J.I.). This work was the result of
using research equipment shared in MEXT project for
promoting public utilization of advanced research infra-
structure (program for supporting introduction of the new
sharing system) Grant JPMXS0422500320.
REFERENCES
■
(1) Zhu, J.; Liu, Y.; Liu, Z.; Wang, H.; Zhang, H. Bioactive
(2) Jang, K. H.; Kang, G. W.; Jeon, J. E.; Lim, C.; Lee, H. S.; Sim, C.
(3) Guo, L.-D.; Huang, X.-Z.; Luo, S.-P.; Cao, W.-S.; Ruan, Y.-P.; Ye,
(4) (a) Luo, S.-P.; Guo, L.-D.; Gao, L.-H.; Li, S.; Huang, P.-Q.
(c) Orihara, K.; Kawagishi, F.; Yokoshima, S.; Fukuyama, T. Synthetic
Synlett 2018, 29, 769−772.
(5) For a representative review, see: (a) Curran, D. P.; Porter, N. A.;
Giese, B. Stereochemistry of Radical Reactions: Concepts, Guidelines, and
Synthetic Applications; VCH: New York, 1995. For a review on
tandem radical reactions, see: (b) Godineau, E.; Landais, Y. Radical
15, 3044−3055.
Lett. 2011, 13, 4778−4781.
ASSOCIATED CONTENT
■
sı
* Supporting Information
The Supporting Information is available free of charge at
Experimental details and compound characterization
(7) For representative examples, see: (a) Herzon, S. B.; Myers, A. G.
127, 5342−5344. (b) Gill, G. B.; Pattenden, G.; Reynolds, S. J.
Chem. Soc., Perkin Trans. 1 1994, 369−378. For a review on acyl and
carbamoyl radicals, see: (c) Chatgilialoglu, C.; Crich, D.; Komatsu,
2070.
AUTHOR INFORMATION
■
Corresponding Author
Jun Ishihara − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan; orcid.org/
Authors
Chem. Soc. 1988, 110, 1288−1290.
Keita Komine − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan
Yasuhiro Urayama − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan
Taku Hosaka − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan
Yuki Yamashita − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan
Hayato Fukuda − Graduate School of Biomedical Sciences,
Nagasaki University, Nagasaki 852-8521, Japan; orcid.org/
cascade. Science 2016, 352, 1078−1082. (c) Hashimoto, S.; Katoh, S.;
(10) Komine, K.; Urayama, Y.; Hosaka, T.; Fukuda, H.;
(11) Bokam, R.; Annam, S. C. V. A. R.; Yalavarthi, N. R.; Gundoju,
Susumi Hatakeyama − Medical Innovation Center, Nagasaki
University, Nagasaki 852-8521, Japan
Complete contact information is available at:
Notes
(12) The enantiomeric ratio was determined by chiral high-
performance liquid chromatography (HPLC) analysis of (+)-15.
The authors declare no competing financial interest.
D
Org. Lett. XXXX, XXX, XXX−XXX